Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NOURA J CHOUDHURY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841649332
CMS profile
1454063
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,282.71

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,225.00 1
Travel and Lodging $930.71 5
Food and Beverage $127.00 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $8,282.71 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NOURA J CHOUDHURY

NPI 1841649332 · CMS profile ID 1454063

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $8,282.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $35.0001/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645695 CMS
GENZYME CORPORATION $115.4101/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645701 CMS
GENZYME CORPORATION $127.2101/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645707 CMS
GENZYME CORPORATION $422.3501/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645711 CMS
GENZYME CORPORATION $7,225.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646101 CMS
GENZYME CORPORATION $230.7401/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646107 CMS
GENZYME CORPORATION $20.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646113 CMS
GENZYME CORPORATION $36.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646121 CMS
GENZYME CORPORATION $71.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646127 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $194.00 2
PY2022 $15.50 1
PY2023 $8,282.71 9
PY2024 $14,757.57 11
PY2025 $15,377.47 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,427.64 2
PY2025 Principal investigator $307,356.67 66
PY2024 Principal investigator $1,388,670.65 463
PY2023 Principal investigator $1,562,080.65 113
PY2022 Principal investigator $223,487.22 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

463 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,400.00 12/31/2024 Non-covered Recipient Entity
DAVID KOCH CENTER FOR CANCER CARE
A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1100764883
Principal investigator 2 Merck Sharp & Dohme LLC $49,136.57 12/31/2024 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na ve Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1136428748
Principal investigator 2 Merck Sharp & Dohme LLC $27,495.60 12/18/2024 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 1136417706
Principal investigator 1 ABBVIE INC. $2,930.00 08/29/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100738030
Principal investigator 1 ABBVIE INC. $607.50 08/22/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1100737580
Principal investigator 1 ABBVIE INC. $4,588.65 08/22/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1100737582
Principal investigator 1 ABBVIE INC. $4,950.00 08/22/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1100737584
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737068
Principal investigator 1 ABBVIE INC. $2,823.80 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737080
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737082
Principal investigator 1 ABBVIE INC. $2,823.80 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737084
Principal investigator 1 ABBVIE INC. $2,315.72 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737086
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737088
Principal investigator 1 ABBVIE INC. $305.10 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737090
Principal investigator 1 ABBVIE INC. $893.70 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737092
Principal investigator 1 ABBVIE INC. $810.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737094
Principal investigator 1 ABBVIE INC. $5,001.75 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737096
Principal investigator 1 ABBVIE INC. $4,508.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737114
Principal investigator 1 ABBVIE INC. $5,001.75 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737116
Principal investigator 1 ABBVIE INC. $2,823.80 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737118
Principal investigator 1 ABBVIE INC. $108.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737120
Principal investigator 1 ABBVIE INC. $2,797.47 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737122
Principal investigator 1 ABBVIE INC. $216.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737124
Principal investigator 1 ABBVIE INC. $2,823.80 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737126
Principal investigator 1 ABBVIE INC. $305.10 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737128
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737138
Principal investigator 1 ABBVIE INC. $2,293.79 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737140
Principal investigator 1 ABBVIE INC. $216.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737142
Principal investigator 1 ABBVIE INC. $5,001.75 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737146
Principal investigator 1 ABBVIE INC. $216.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737148
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737150
Principal investigator 1 ABBVIE INC. $4,508.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737152
Principal investigator 1 ABBVIE INC. $810.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737154
Principal investigator 1 ABBVIE INC. $5,001.75 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737156
Principal investigator 1 ABBVIE INC. $108.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737158
Principal investigator 1 ABBVIE INC. $1,340.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737160
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737162
Principal investigator 1 ABBVIE INC. $810.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737166
Principal investigator 1 ABBVIE INC. $893.70 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737168
Principal investigator 1 ABBVIE INC. $108.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737170
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737172
Principal investigator 1 ABBVIE INC. $4,508.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737174
Principal investigator 1 ABBVIE INC. $810.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737176
Principal investigator 1 ABBVIE INC. $893.70 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737178
Principal investigator 1 ABBVIE INC. $5,001.75 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737180
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737182
Principal investigator 1 ABBVIE INC. $2,797.47 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737184
Principal investigator 1 ABBVIE INC. $2,797.47 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737186
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737188
Principal investigator 1 ABBVIE INC. $2,315.72 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737192
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737194
Principal investigator 1 ABBVIE INC. $216.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737196
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737198
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737208
Principal investigator 1 ABBVIE INC. $305.10 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737212
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737214
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737216
Principal investigator 1 ABBVIE INC. $4,508.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737218
Principal investigator 1 ABBVIE INC. $446.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737220
Principal investigator 1 ABBVIE INC. $2,293.79 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737270
Principal investigator 1 ABBVIE INC. $810.00 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737278
Principal investigator 1 ABBVIE INC. $1,340.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737280
Principal investigator 1 ABBVIE INC. $4,508.85 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737282
Principal investigator 1 ABBVIE INC. $152.55 08/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100737284
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735980
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735988
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735994
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735996
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736000
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736002
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736004
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736006
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736008
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736016
Principal investigator 1 ABBVIE INC. $2,994.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736018
Principal investigator 1 ABBVIE INC. $3,811.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736020
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736026
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736028
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736030
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736032
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736034
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736036
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736038
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736044
Principal investigator 1 ABBVIE INC. $3,811.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736046
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736048
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736050
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736052
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736054
Principal investigator 1 ABBVIE INC. $2,930.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736056
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736060
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736062
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736064
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736080
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736082
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736096
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736098
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736106
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736108
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736110
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736134
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736140
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736142
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736144
Principal investigator 1 ABBVIE INC. $2,994.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736180
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736182
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736184
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736212
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736214
Principal investigator 1 ABBVIE INC. $2,930.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736216
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736238
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736240
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736242
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736244
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736246
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736342
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736350
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736354
Principal investigator 1 ABBVIE INC. $2,643.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736356
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736512
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736524
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736544
Principal investigator 1 ABBVIE INC. $2,930.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736552
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736562
Principal investigator 1 ABBVIE INC. $1,600.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736566
Principal investigator 1 ABBVIE INC. $4,432.00 08/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100736572
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735286
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735288
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735294
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735298
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735304
Principal investigator 1 ABBVIE INC. $2,823.80 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735306
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735308
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735310
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735314
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735316
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735318
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735322
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735326
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735328
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735330
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735332
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735336
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735340
Principal investigator 1 ABBVIE INC. $2,823.80 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735342
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735346
Principal investigator 1 ABBVIE INC. $2,797.47 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735348
Principal investigator 1 ABBVIE INC. $2,823.80 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735350
Principal investigator 1 ABBVIE INC. $2,823.80 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735380
Principal investigator 1 ABBVIE INC. $2,293.79 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735436
Principal investigator 1 ABBVIE INC. $2,315.72 08/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100735438
Principal investigator 1 ABBVIE INC. $5,351.00 08/01/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100732586
Principal investigator 1 ABBVIE INC. $4,432.00 08/01/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100732626
Principal investigator 1 ABBVIE INC. $10,647.00 06/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100724996
Principal investigator 1 ABBVIE INC. $2,187.00 06/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100724998
Principal investigator 1 ABBVIE INC. $2,892.00 06/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100725002
Principal investigator 1 ABBVIE INC. $4,481.00 06/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100725004
Principal investigator 1 Amgen Inc. $11,720.38 06/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer No dispute reported 06/30/2026 1096308795
Principal investigator 1 ABBVIE INC. $2,293.79 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723628
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723630
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723632
Principal investigator 1 ABBVIE INC. $810.00 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723634
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723636
Principal investigator 1 ABBVIE INC. $2,315.72 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723638
Principal investigator 1 ABBVIE INC. $216.00 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723640
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723642
Principal investigator 1 ABBVIE INC. $2,797.47 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723644
Principal investigator 1 ABBVIE INC. $2,797.47 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723646
Principal investigator 1 ABBVIE INC. $5,001.75 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723648
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723650
Principal investigator 1 ABBVIE INC. $2,315.72 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723652
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723654
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723656
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723658
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723660
Principal investigator 1 ABBVIE INC. $4,508.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723662
Principal investigator 1 ABBVIE INC. $893.70 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723664
Principal investigator 1 ABBVIE INC. $2,293.79 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723666
Principal investigator 1 ABBVIE INC. $2,315.72 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723668
Principal investigator 1 ABBVIE INC. $2,797.47 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723670
Principal investigator 1 ABBVIE INC. $2,315.72 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723672
Principal investigator 1 ABBVIE INC. $2,797.47 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723674
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723676
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723678
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723680
Principal investigator 1 ABBVIE INC. $2,315.72 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723682
Principal investigator 1 ABBVIE INC. $256.50 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723684
Principal investigator 1 ABBVIE INC. $2,293.79 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723686
Principal investigator 1 ABBVIE INC. $2,823.80 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723688
Principal investigator 1 ABBVIE INC. $2,797.47 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723690
Principal investigator 1 ABBVIE INC. $2,315.72 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723692
Principal investigator 1 ABBVIE INC. $2,823.80 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723694
Principal investigator 1 ABBVIE INC. $2,293.79 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723696
Principal investigator 1 ABBVIE INC. $2,293.79 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723698
Principal investigator 1 ABBVIE INC. $446.85 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723700
Principal investigator 1 ABBVIE INC. $152.55 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723702
Principal investigator 1 ABBVIE INC. $2,293.79 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723704
Principal investigator 1 ABBVIE INC. $2,797.47 06/14/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100723706
Principal investigator 1 ABBVIE INC. $2,315.72 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720378
Principal investigator 1 ABBVIE INC. $446.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720384
Principal investigator 1 ABBVIE INC. $4,508.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720392
Principal investigator 1 ABBVIE INC. $4,508.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720394
Principal investigator 1 ABBVIE INC. $2,293.79 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720396
Principal investigator 1 ABBVIE INC. $152.55 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720398
Principal investigator 1 ABBVIE INC. $2,797.47 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720400
Principal investigator 1 ABBVIE INC. $216.00 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720402
Principal investigator 1 ABBVIE INC. $446.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720404
Principal investigator 1 ABBVIE INC. $446.45 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720406
Principal investigator 1 ABBVIE INC. $446.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720408
Principal investigator 1 ABBVIE INC. $5,001.75 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720410
Principal investigator 1 ABBVIE INC. $2,823.80 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720420
Principal investigator 1 ABBVIE INC. $108.00 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720422
Principal investigator 1 ABBVIE INC. $446.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720424
Principal investigator 1 ABBVIE INC. $810.00 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720426
Principal investigator 1 ABBVIE INC. $2,293.79 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720428
Principal investigator 1 ABBVIE INC. $2,823.80 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720430
Principal investigator 1 ABBVIE INC. $810.00 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720438
Principal investigator 1 ABBVIE INC. $5,001.75 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720440
Principal investigator 1 ABBVIE INC. $152.55 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720442
Principal investigator 1 ABBVIE INC. $2,797.47 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720444
Principal investigator 1 ABBVIE INC. $4,508.85 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720446
Principal investigator 1 ABBVIE INC. $5,304.62 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720448
Principal investigator 1 ABBVIE INC. $5,001.75 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720450
Principal investigator 1 ABBVIE INC. $152.55 06/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720452
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719882
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719884
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719886
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719890
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719892
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719898
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719900
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719902
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719904
Principal investigator 1 ABBVIE INC. $108.00 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719906
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719920
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719922
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719936
Principal investigator 1 ABBVIE INC. $108.00 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719938
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719940
Principal investigator 1 ABBVIE INC. $216.00 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719942
Principal investigator 1 ABBVIE INC. $108.00 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719944
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719972
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719974
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719976
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719978
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719980
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720002
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720004
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720006
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720018
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720020
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720022
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720024
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720026
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720028
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720030
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720032
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720062
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720064
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720066
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720068
Principal investigator 1 ABBVIE INC. $810.00 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720152
Principal investigator 1 ABBVIE INC. $108.00 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720154
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720162
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720164
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720166
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720168
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720230
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720232
Principal investigator 1 ABBVIE INC. $446.85 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720236
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720238
Principal investigator 1 ABBVIE INC. $152.55 05/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100720240
Principal investigator 1 ABBVIE INC. $2,643.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718862
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718864
Principal investigator 1 ABBVIE INC. $2,643.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718866
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718868
Principal investigator 1 ABBVIE INC. $2,643.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718870
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718890
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718892
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718894
Principal investigator 1 ABBVIE INC. $2,994.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718896
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718898
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718900
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718902
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718904
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100718906
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719020
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719040
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719042
Principal investigator 1 ABBVIE INC. $2,510.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719114
Principal investigator 1 ABBVIE INC. $3,035.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719116
Principal investigator 1 ABBVIE INC. $5,351.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719118
Principal investigator 1 ABBVIE INC. $2,643.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719138
Principal investigator 1 ABBVIE INC. $2,510.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719140
Principal investigator 1 ABBVIE INC. $5,351.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719142
Principal investigator 1 ABBVIE INC. $2,510.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719144
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719156
Principal investigator 1 ABBVIE INC. $3,035.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719158
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719160
Principal investigator 1 ABBVIE INC. $2,643.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719162
Principal investigator 1 ABBVIE INC. $2,930.00 05/20/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100719164
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714228
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714230
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714240
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714244
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714246
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714252
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714254
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714256
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714258
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714260
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714262
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714264
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714268
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714276
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714284
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714286
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714288
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714290
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714294
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714296
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714298
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714300
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714334
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714336
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714338
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714340
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714342
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714344
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714354
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714356
Principal investigator 1 ABBVIE INC. $2,823.80 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714358
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714386
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714390
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714396
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714398
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714514
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714516
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714518
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714520
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714522
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714576
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714578
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714580
Principal investigator 1 ABBVIE INC. $2,797.47 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714582
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714584
Principal investigator 1 ABBVIE INC. $2,293.79 04/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714586
Principal investigator 1 ABBVIE INC. $5,630.11 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714084
Principal investigator 1 ABBVIE INC. $5,001.75 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714086
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714090
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714092
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714094
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714098
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714102
Principal investigator 1 ABBVIE INC. $5,630.11 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714106
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714108
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714110
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714112
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714114
Principal investigator 1 ABBVIE INC. $5,630.11 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714118
Principal investigator 1 ABBVIE INC. $4,508.85 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714120
Principal investigator 1 ABBVIE INC. $4,508.85 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714122
Principal investigator 1 ABBVIE INC. $810.00 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714124
Principal investigator 1 ABBVIE INC. $5,630.11 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714128
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714130
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714132
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714134
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714136
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714138
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714140
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714142
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714144
Principal investigator 1 ABBVIE INC. $2,315.72 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714146
Principal investigator 1 ABBVIE INC. $5,630.11 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714150
Principal investigator 1 ABBVIE INC. $5,001.75 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714154
Principal investigator 1 ABBVIE INC. $5,001.75 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714158
Principal investigator 1 ABBVIE INC. $4,508.85 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714160
Principal investigator 1 ABBVIE INC. $4,508.85 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714162
Principal investigator 1 ABBVIE INC. $810.00 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714164
Principal investigator 1 ABBVIE INC. $810.00 04/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100714194
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710152
Principal investigator 1 ABBVIE INC. $4,432.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710154
Principal investigator 1 ABBVIE INC. $4,432.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710156
Principal investigator 1 ABBVIE INC. $2,994.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710158
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710160
Principal investigator 1 ABBVIE INC. $4,432.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710166
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710170
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710172
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710176
Principal investigator 1 ABBVIE INC. $4,432.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710178
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710180
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710182
Principal investigator 1 ABBVIE INC. $4,244.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710184
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710186
Principal investigator 1 ABBVIE INC. $2,994.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710188
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710208
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710210
Principal investigator 1 ABBVIE INC. $2,643.00 03/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710212
Principal investigator 1 ABBVIE INC. $4,432.00 03/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100708971
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707811
Principal investigator 1 ABBVIE INC. $4,607.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707813
Principal investigator 1 ABBVIE INC. $2,994.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707815
Principal investigator 1 ABBVIE INC. $2,930.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707817
Principal investigator 1 ABBVIE INC. $2,930.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707819
Principal investigator 1 ABBVIE INC. $2,930.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707821
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707823
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707825
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707827
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707829
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707831
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707833
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707835
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707837
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707839
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707841
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707843
Principal investigator 1 ABBVIE INC. $2,994.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707845
Principal investigator 1 ABBVIE INC. $4,244.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707847
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707849
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707851
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707853
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707855
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707857
Principal investigator 1 ABBVIE INC. $4,244.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707859
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707861
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707863
Principal investigator 1 ABBVIE INC. $4,607.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707865
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707867
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707869
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707871
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707873
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707875
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707877
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707879
Principal investigator 1 ABBVIE INC. $1,600.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707881
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707883
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707885
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707887
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707889
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707891
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707895
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707897
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707899
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707901
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707903
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707905
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707907
Principal investigator 1 ABBVIE INC. $3,035.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707909
Principal investigator 1 ABBVIE INC. $2,930.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707911
Principal investigator 1 ABBVIE INC. $3,035.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707913
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707915
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707917
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707919
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707921
Principal investigator 1 ABBVIE INC. $2,994.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707923
Principal investigator 1 ABBVIE INC. $2,994.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707925
Principal investigator 1 ABBVIE INC. $4,244.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707927
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707929
Principal investigator 1 ABBVIE INC. $4,432.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707931
Principal investigator 1 ABBVIE INC. $2,643.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707933
Principal investigator 1 ABBVIE INC. $5,351.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707967
Principal investigator 1 ABBVIE INC. $2,971.00 03/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100707969
Principal investigator 1 Amgen Inc. $184,722.48 01/23/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
P3 2L SCLC 2-Arm Mono 757 vs SOC . No dispute reported 06/30/2026 1096313263